Seer (NASDAQ:SEER – Get Free Report) will be issuing its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Seer has set its FY 2024 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.
Seer (NASDAQ:SEER – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. Seer had a negative net margin of 559.21% and a negative return on equity of 21.26%. The business had revenue of $3.07 million during the quarter, compared to analysts’ expectations of $3.33 million. During the same quarter in the prior year, the business posted ($0.37) EPS. On average, analysts expect Seer to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Seer Stock Performance
Shares of Seer stock opened at $2.02 on Tuesday. The company has a fifty day simple moving average of $1.82 and a 200-day simple moving average of $1.83. Seer has a 12-month low of $1.46 and a 12-month high of $2.30.
Analysts Set New Price Targets
Read Our Latest Report on Seer
Seer Company Profile
Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
See Also
- Five stocks we like better than Seer
- Comparing and Trading High PE Ratio Stocks
- Intel: Is Now the Time to Be Brave?Â
- 3 Fintech Stocks With Good 2021 Prospects
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a buyback in stocks? A comprehensive guide for investors
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.